1505 related articles for article (PubMed ID: 16483267)
1. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
2. Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease.
Katz PO
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():3-11. PubMed ID: 16483265
[TBL] [Abstract][Full Text] [Related]
3. Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease--Bilitec, intraluminal impedance and Bravo capsule pH monitoring.
Hirano I
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():12-24. PubMed ID: 16483266
[TBL] [Abstract][Full Text] [Related]
4. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
DeVault KR
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
[TBL] [Abstract][Full Text] [Related]
5. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
6. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?
Tack J; Koek G; Demedts I; Sifrim D; Janssens J
Am J Gastroenterol; 2004 Jun; 99(6):981-8. PubMed ID: 15180713
[TBL] [Abstract][Full Text] [Related]
7. Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms.
Sifrim D; Mittal R; Fass R; Smout A; Castell D; Tack J; Gregersen H
Aliment Pharmacol Ther; 2007 May; 25(9):1003-17. PubMed ID: 17439501
[TBL] [Abstract][Full Text] [Related]
8. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
[TBL] [Abstract][Full Text] [Related]
9. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
Armstrong D
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
[TBL] [Abstract][Full Text] [Related]
10. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
11. Gastroesophageal reflux disease symptoms on antisecretory therapy: acid, non-acid, or no GERD.
Katz PO
Rev Gastroenterol Disord; 2006; 6(3):136-45. PubMed ID: 16957654
[TBL] [Abstract][Full Text] [Related]
12. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces.
Farré R; van Malenstein H; De Vos R; Geboes K; Depoortere I; Vanden Berghe P; Fornari F; Blondeau K; Mertens V; Tack J; Sifrim D
Gut; 2008 Oct; 57(10):1366-74. PubMed ID: 18593808
[TBL] [Abstract][Full Text] [Related]
13. Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease?
Vakil N
Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():64-9. PubMed ID: 16042661
[TBL] [Abstract][Full Text] [Related]
14. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).
Milkes D; Gerson LB; Triadafilopoulos G
Am J Gastroenterol; 2004 Jun; 99(6):991-6. PubMed ID: 15180715
[TBL] [Abstract][Full Text] [Related]
15. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus.
Emerenziani S; Sifrim D; Habib FI; Ribolsi M; Guarino MP; Rizzi M; Caviglia R; Petitti T; Cicala M
Gut; 2008 Apr; 57(4):443-7. PubMed ID: 17766596
[TBL] [Abstract][Full Text] [Related]
16. Review article: complete gastro-oesophageal reflux monitoring - combined pH and impedance.
Tutuian R; Castell DO
Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 2():27-37. PubMed ID: 16939430
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
18. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal gastric acidity pattern in gastro-oesophageal reflux disease with or without oesophagitis.
Sozzi M; Valentini M; Poletti M; Bertolissi E; Serraino D; Bovero E; De Iaco F
Ital J Gastroenterol; 1995; 27(8):413-8. PubMed ID: 8775466
[TBL] [Abstract][Full Text] [Related]
20. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Gardner JD; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
